Ok, I am skeptical of any reports about "breakthroughs" in treatment of ovarian cancer, but there is a report from the New England Journal of Medicine about intraperitoneal (IP) chemotherapy delivered through the abdomen as a better form of treatment than traditional intravenous (IV) approaches. The benefit is a longer median survival time by an average of 16 months. So while this is not a cure by any means, it can significantly extend the lives of ovarian cancer patients.
- ABC TV: Ovarian Cancer Breakthrough
- National Cancer Institute: IP Chemo Press Release
- National Cancer Institute: IP Chemo Q&A
Comments